Skip to content

Twice Weekly Steroids and Exercise as Therapy for DMD

Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle Function

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04322357
Enrollment
21
Registered
2020-03-26
Start date
2020-07-30
Completion date
2025-09-04
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy (DMD)

Keywords

novel steroid regimen, twice-weekly prednisone, exercise training, leg cycling, isometric strengthening

Brief summary

The study team will determine the potential of low dose twice weekly prednisone and whether exercise training can synergize to delay disease progression and improve muscle strength/physical function in boys with Duchenne muscular dystrophy (DMD). Current standard of care (daily prednisone) is associated with adverse side effects. Evidence from DMD mouse models suggest that weekly dosing provides same efficacy without side effects. Appropriate exercise may also benefit but this area has not been adequately explored.

Detailed description

This innovative proposal focuses on developing an efficacious therapeutic strategy involving low dose twice weekly glucocorticoid (GC) administration and exercise training for boys affected with Duchenne muscular dystrophy (DMD), a currently incurable disease characterized by rapidly progressive muscle weakness, early loss of ambulation and death. While GC are the only proven treatment to reduce fibrosis and delay loss of ambulation in DMD, chronic daily administration (which is most commonly prescribed) is associated with adverse, often debilitating effects. As an alternate dosing regimen, weekend-only use was shown to retain the benefits and have less impact on weight gain and linear growth, however high doses were used and associated with behavioral issues. Recent work in mice suggests that the same daily dose administered transiently may be effective and have a greater impact on gains in muscle mass, strength and resistance to fatigue compared to daily dosing due to differential effects on gene expression signaling pathways important for muscle remodeling. Exercise, which also induces signaling pathways that lead to remodeling in healthy muscle, may beneficially impact pathophysiology of DMD by recruiting compensatory pathways. Although high intensity or eccentric actions are damaging to dystrophic muscle, a few studies suggest that submaximal exercise is safe and may delay the loss of muscle function in boys with DMD. Despite these exploratory studies suggesting potential, there is a paucity of research on exercise, which reflects our current lack of understanding of specific exercise prescription parameters (type, intensity, target muscle groups) that may be safe and effective for patients with DMD, as well as lack of accessibility to exercise equipment that appropriately and sufficiently induces adaptation in dystrophic muscle. The objective of this work is to define an efficacious GC regimen with minimal side effects, and understand if exercise training can potentially delay disease progression, reverse secondary effects of disuse, and induce beneficial adaptations in boys with DMD. AIM 1: To determine the 12-month impact of a low dose (0.75 mg/kg x 2 days of prednisone) regimen on weight gain, DMD muscle pathophysiology and physical function. We hypothesize that compared to the standard daily regimen, a twice-weekly regimen will have less impact on body mass index, and equal improvements in the 1-year change in physical function and muscle fat fraction. AIM 2: To determine impact of a 6-month in-home, moderate intensity, leg exercise training program on muscle pathophysiology and physical function in DMD.

Interventions

DRUGPrednisone

A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).

BEHAVIORALExercise Training on standard steroid regimen

For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.

DRUGExercise training on twice-weekly steroids

Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.

Sponsors

University of Florida
Lead SponsorOTHER
U.S. Army Medical Research and Development Command
CollaboratorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
5 Years to 9 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of DMD confirmed by 1) clinical history with features before the age of five, 2) physical examination, 3) elevated serum creatine kinase level and 4) absence of dystrophin expression, as determined by immunostain or Western blot (\<2%) and/or DNA confirmation of dystrophin mutation. * Age 5.0 to 9 years: a lower age limit of 5.0 years is selected as children younger than that are likely unable to cooperate and comply with all of the exercise measures as needed. An upper age limit of 9 years has been set as boys with DMD tend to reach a rapid progression into a late ambulatory phase soon after this age. * Ambulatory at the time of the first visit, defined as the ability to walk for at least 100 m without an external assistive device and able to climb four stairs. * Aim 1 only: GC-naïve at baseline (and prior 6 months) * Aim 2 only: on stable daily GC regimen for 6 months prior to baseline

Exclusion criteria

* Contraindication to an MR examination (e.g. aneurysm clip, severe claustrophobia, magnetic implants) * Presence of unstable medical problems, significant concomitant illness including cardiomyopathy or cardiac conduction abnormalities * Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease) * Presence of a secondary condition leading to developmental delay or impaired motor control (e.g. cerebral palsy) * Presence of an unstable medical condition (e.g. uncontrolled seizure disorder) * Behavioral problems causing an inability to cooperate during testing or understand exercise instruction * Participation in other forms of drug or gene therapy during the period of the study

Design outcomes

Primary

MeasureTime frameDescription
Change in BMIBaseline up to 12 monthsParticipant body mass index change (weight and height will be combined to report BMI in kg/m\^2) over the course of one year

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORTanja Taivassalo, MD

University of Florida

Participant flow

Pre-assignment details

21 patients were enrolled in the study. Of these, 17 steroid-naive boys with DMD were enrolled into the 12 month twice weekly steroid arm and 2 of the 17 underwent cycle exercise training from month 6 to 12. Of the 21 enrolled patients, 4 boys on daily steroids were enrolled into a 6-month exercise training arm.

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
4 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Age, Continuous6.2 years
STANDARD_DEVIATION 1.7
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
12 Participants
Region of Enrollment
Canada
2 participants
Region of Enrollment
Finland
1 participants
Region of Enrollment
United States
18 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 150 / 40 / 2
other
Total, other adverse events
3 / 170 / 40 / 2
serious
Total, serious adverse events
1 / 150 / 40 / 2

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026